Companion Animal Arthritis Market Report 2026

Companion Animal Arthritis Market Overview

• Companion Animal Arthritis market size has reached to $4.07 billion in 2025 • Expected to grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Growing Trend Of Pet Adoption Boosts The Companion Animal Arthritis Market • Market Trend: Advancements In Monoclonal Antibody Therapy For Companion Animal Arthritis Treatment • North America was the largest region in 2025.

What Is Covered Under Companion Animal Arthritis Market?

The companion animal arthritis refers to a condition involving inflammation of one or more joints in companion animals such as cats, dogs, and other exotic animals. Companion animal arthritis develops in the bones when the cartilage between joints becomes rougher and more worn, forcing the bone surfaces to rub against one another. The main type of companion animal arthritis are dogs, cats, and other types. The dogs companion animal arthritis is used for controlling pain and inflammation in dogs. Dogs are domesticated canines (Canis familiaris) that are usually kept as pets or trained for hunting, guarding individuals, or property. The companion animal arthritis indication are osteoarthritis and, other arthritis, that are treatment through medication, supplements and other treatment, which are sold and distributed through veterinary hospitals and clinics, retail pharmacies, online stores, and others.

What Is The Companion Animal Arthritis Market Growth Forecast?

The companion animal arthritis market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising pet humanization trends, increasing demand for advanced arthritis therapies, growth in senior pet population, expansion of online veterinary pharmacies, innovation in combination therapies and supplements. Major trends in the forecast period include rising prevalence of age-related arthritis in pets, increasing pet owner spending on chronic care, growing adoption of nutraceuticals and joint supplements, shift toward early diagnosis and preventive treatment, rising demand for long-term pain management solutions.

Global Companion Animal Arthritis Market Segmentation

1) By Type: Dogs, Cats, Other Types 2) By Indication: Osteoarthritis, Inflammatory Arthritis 3) By Treatment: Medication, Supplements, Other Treatments 4) By Distribution Channel: Veterinary Hospitals And Clinics, Retail Pharmacies, Online Stores, Other Distribution Channels Subsegments: 1) By Dogs: Large Breed Dogs, Small Breed Dogs, Senior Dogs 2) By Cats: Domestic Cats, Senior Cats 3) By Other Types: Rabbits, Ferrets

What Is The Driver Of The Companion Animal Arthritis Market?

Rising trend of pet adoption is expected to propel the growth of companion animal arthritis market. Pet adoption refers to the process of taking responsibility for a pet from a shelter or previous owner and providing it with care, food, and a safe home. Pet adoption is rising due to growing emotional awareness, as more people seek companionship and mental well-being through caring for animals. Companion animal arthritis treatments support pet adoption by giving potential owners confidence that age-related joint issues can be managed, making older pets easier to care for and more adoptable. For instance, in 2024, according to the Shelter Animals Count (SAC), a US-based nonprofit organization, dog adoption rates (percentage of adoptions relative to intakes) have increased 56% in 2023 to 57% in 2024. Therefore, the rising trend of pet adoption contributes significantly to the growth of the companion animal arthritis industry.

Key Players In The Global Companion Animal Arthritis Market

Major companies operating in the companion animal arthritis market are Zoetis Inc., Merck Animal Health, Boehringer Ingelheim, Bayer Animal Health, Vetoquinol, Ceva Santé Animale, Dechra Pharmaceuticals, PetMed Express, Pet Health Solutions, VetriScience, Canine Arthritis Management, Integrative Pet Care, The Honest Kitchen, Vetri-Science Laboratories, Anivive Lifesciences, Nutramax Laboratories, Hill's Pet Nutrition, Royal Canin, Medivet, Virbac, Canna-Pet, Lintbells, Allivet, Petlab Co.

Global Companion Animal Arthritis Market Trends and Insights

Major companies in the companion animal arthritis market are increasingly focusing on technological innovations, such as advanced therapeutic products and supplements, to provide pets with effective pain relief and improved joint health, ensuring a higher quality of life for aging and arthritis-affected animals. Bonqat is a new medication developed for cats that helps reduce anxiety during stressful situations, such as travel or veterinary visits, without causing sedation. The product aims to calm cats, making it easier for them and their owners during trips or appointments. For instance, in April 2024, Zoetis Inc., a US-based company which manufactures medicine and vaccinations for pets and livestock, launched Bonqat (pregabalin oral solution) for alleviation of feline acute anxiety and fear associated with transportation and veterinary visits, which can be a barrier to routine care. The oral solution can be mixed with food or given directly to the cat, making it easier for pet owners to administer. The dosing is small (0.1 mL/kg), and a majority of cat owners have reported that administration is easy.

What Are Latest Mergers And Acquisitions In The Companion Animal Arthritis Market?

In January 2024, Ceva Santé Animale S.A., a France‑based provider of animal health solutions including preventive medicine (vaccines), pharmaceutical products for farm and companion animals, animal welfare products, and related equipment and services, acquired Scout Bio Inc. for an undisclosed amount. With this acquisition, Ceva aims to accelerate its global biotechnology efforts and expand its biotherapeutic capabilities by integrating Scout Bio’s pipeline of monoclonal antibodies and gene therapy innovations to address chronic diseases in pets, enhancing its position in cutting‑edge pet therapeutics. Scout Bio Inc. is a US‑based biotechnology company specializing in the development of novel biotherapeutic products for pets, including one‑time gene therapies and monoclonal antibody treatments designed to induce long‑term therapeutic protein expression for chronic animal health conditions.

Regional Outlook

North America was the largest region in the companion animal arthritis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Companion Animal Arthritis Market?

The companion animal arthritis market includes revenues earned by entities by NSAIDs, monoclonal antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.